KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kiniksa Pharmaceuticals International, plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$79.48+0.89 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $6.63B
- P/E (TTM)
- 81.9
- Dividend yield
- –
Kiniksa Pharmaceuticals International, plc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $243.60M | $214.27M | $202.13M | $180.86M | $156.80M | $137.79M | $122.54M | $112.21M | $103.39M | $78.89M | $71.22M | $64.80M | 100.0% | +55.4% |
| License and collaboration revenue | – | – | – | – | – | – | $0 | $0 | $5.24M | $973.00K | $12.18M | $2.24M | – | – |
By region
From the segment and revenue-disaggregation notes of Kiniksa Pharmaceuticals International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.